A Retrospective Analysis of Real-World Discontinuation Rates with Delayed-Release Dimethyl Fumarate in Patients with Relapsing–Remitting Multiple Sclerosis
Sign Up to like & getrecommendations! Published in 2019 at "Neurology and Therapy"
DOI: 10.1007/s40120-019-00174-3
Abstract: Introduction The main objective of this study was to examine discontinuation rates associated with delayed-release dimethyl fumarate (DMF) when used for the treatment of relapsing multiple sclerosis (MS) in a real-world, clinical practice setting. Methods… read more here.
Keywords: real world; dmf; discontinuation; discontinuation rates ... See more keywords
Comparing Long-Acting Antipsychotic Discontinuation Rates Under Ordinary Clinical Circumstances: A Survival Analysis from an Observational, Pragmatic Study
Sign Up to like & getrecommendations! Published in 2021 at "CNS Drugs"
DOI: 10.1007/s40263-021-00809-w
Abstract: Recent guidelines suggested a wider use of long-acting injectable antipsychotics (LAI) than previously, but naturalistic data on the consequences of LAI use in terms of discontinuation rates and associated factors are still sparse, making it… read more here.
Keywords: long acting; clinical circumstances; study; lai ... See more keywords
Discontinuation rates attributed to adverse events and treatment outcomes between clarithromycin and azithromycin in Mycobacterium avium complex lung disease: A propensity score analysis.
Sign Up to like & getrecommendations! Published in 2020 at "Journal of global antimicrobial resistance"
DOI: 10.1016/j.jgar.2020.01.004
Abstract: OBJECTIVES We aimed to compare the discontinuation rates attributed to adverse events and treatment outcomes between clarithromycin and azithromycin in patients with Mycobacterium avium complex lung disease (MAC-LD). METHODS Among patients diagnosed with MAC-LD in… read more here.
Keywords: analysis; attributed adverse; treatment; discontinuation ... See more keywords
Adverse Events and Discontinuation Rates Associated with Sirolimus Treatment in Adult Renal Transplant Patients in Latin America vs Non-Latin American Countries.
Sign Up to like & getrecommendations! Published in 2020 at "Transplantation proceedings"
DOI: 10.1016/j.transproceed.2020.01.040
Abstract: BACKGROUND Sirolimus is approved for prophylaxis of organ rejection following renal transplantation. Rates of treatment-emergent adverse events (TEAEs) leading to sirolimus discontinuation differ geographically. METHODS Rates of TEAEs, serious AEs (SAEs), and discontinuations were evaluated… read more here.
Keywords: treatment; latin america; renal transplant; discontinuation ... See more keywords
Discontinuation Rates of Tadalafil Alone and in Combination with a-Blockers in the Treatment of Male Lower Urinary Tract Symptoms with or without Coexisting Erectile Dysfunction: A Systematic Review and Meta-Analysis
Sign Up to like & getrecommendations! Published in 2022 at "International Journal of Clinical Practice"
DOI: 10.1155/2022/9298483
Abstract: Purpose We examined the discontinuation rates of tadalafil alone and in combination with a-blockers (ABs) for the treatment of male lower urinary tract symptoms (LUTS), with or without erectile dysfunction (ED). Materials and Methods We… read more here.
Keywords: tadalafil alone; discontinuation rates; combination; alone combination ... See more keywords
Discontinuation rates of intrauterine contraception due to unfavourable bleeding: a systematic review
Sign Up to like & getrecommendations! Published in 2022 at "BMC Women's Health"
DOI: 10.1186/s12905-022-01657-6
Abstract: Objective Levonorgestrel-releasing intrauterine devices (LNG-IUDs) and copper intrauterine devices (Cu-IUDs) offer long-acting contraception; however, some women may discontinue use within the first year due to bleeding pattern changes, limiting their potential. This systematic literature review… read more here.
Keywords: discontinuation rates; bleeding; discontinuation; lng iuds ... See more keywords
Dosing, drug reduction, drug interruption, and drug discontinuation rates among U.S. FDA approved tyrosine kinase inhibitors.
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2021.39.15_suppl.3112
Abstract: 3112 Background: The advent of tyrosine kinase inhibitors (TKIs) has altered the therapeutic landscape of multiple hematological and solid malignancies. FDA approved starting doses of TKIs are based on the recommended phase 2 dose (RP2D)… read more here.
Keywords: fda approved; drug; discontinuation rates; drug discontinuation ... See more keywords